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INTRODUCTION
The protein α-Synuclein is found in the neurons of
mammalian cells. Although not fully understood, it has been
hypothesized that α-Synuclein plays a role in membrane
binding and the monitoring of neurotransmitter
concentrations. Using yeast as a model organism has shown
to be an affective way of observing these human proteins
because of its ability to mimic the aggregation and
cytotoxicity of α-Synuclein in human pathology. After
imaging cells that were overexpressing α-Synuclein, drug
therapies were introduced to see how they might affect
protein aggregation. Phenylmethylsulfonyl fluoride (PMSF)
and Sulforaphane (SFN) have shown the ability to alleviate
protein aggregation.
FIGURE 4: Hitox was grown for approximately 12 hours
in YPD liquid media, washed, and resuspended in YEP
Raffinose in order to prep the galactose promoter. After 3
hours, the cultures were washed and resuspended into YEP
Galactose for 3 hours, after which drugs were introduced.
For both figures (A) and (B), the P value proved to be
insignificant. This shows that neither PMSF nor SFN had
an affect on GFP intensity.
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ABSTRACT
Parkinson’s Disease, PD, is the second most common
neurodegenerative disease in humans. PD is marked by
Lewy body formation in the brain, which disturbs the
dopamine transfer system across neurons. Previous studies
have shown that the protein, α-Synuclein, is a major
contributor in the formation of Lewy bodies. In this study,
we modeled α-Synuclein aggregation in the Budding Yeast,
Saccharomyces cerevisiae and treated the cells with
Phenylmethylsulfonyl fluoride (PMSF) in one trial, and
Sulforaphane (SFN) in another. Our goal was to see how
PMSF and SFN might affect aggregation, while also
monitoring the health of the yeast. Our Preliminary data has
suggested that a 4mM concentration of PMSF and 200μg/ml
of SFN significantly reduces protein aggregation. Our lab
will continue to investigate the role of PMSF and SFN in the
prevention and breakdown of α-Synuclein aggregates.
CONCLUSIONS
• α-Synuclein aggregates and is toxic in budding
yeast.
•PMSF and SFN appear to alleviate protein
aggregation.
FIGURE 1: Parkinson’s Disease has been linked 
to alpha-synuclein aggregation in Lewy Bodies
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Figure 3: Two strains of Saccharomyces cerevisiae were used in this study, 4791 and 4795. 4791 is a
high-tox strain expressing 3x α-Synuclein, whereas low-tox is expressing 1x α-Synuclein. The figure
above shows that the galactose promoter was turned on at T=3. At T=3, separate cell cultures were given
drugs. Aggregate reduction is clear in the pictures at T=7 when compared to the control. In this
experiment, both cell strains were grown for 12hrs in YEP glucose liquid media, washed and transferred
to YEP raffinose for 3 hours. In the induction step, cultures were washed and inoculated into YEP
galactose.
FIGURE 4: PMSF and SFN Do Not Alter 
a-synuclein-GFP Protein Levels in Hitox Cells
(A) PMSF Does Not Reduce Alpha-Synuclein-GFP Levels in Hitox Cells
(B) SFN Does Not Reduce Alpha-Synuclein-GFP Levels in Hitox Cells
FIGURE 2: Overexpression of Human a-synuclein in Yeast Triggers Aggregation
Figure 2: Two strains of wildtype yeast cells in the W303 strain background with one
copy (LOTOX) and three copies (HITOX) of a galactose inducible construct expressing


















FIGURE 3: PMSF and Sulforaphane (SFN) Reduce a-synuclein Aggregation in Yeast  
YEP Galactose
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